Goal 1: Promote Human Health

Nefarious substances in the US blood supply

Prescription and illicit drug is everpresent in the US, which can potentially result in controlled substances entering the US blood supply. Passive transfer of immune allergens is only anecdotally been reported as peanut allergens, fish allergens, and contrast material. However, US blood donors are only screened for a limited number of medications on the universal donor health questionnaire at time of collection. What, ...more »

Submitted by (@garrett.s.booth)

Voting

-11 net votes
6 up votes
17 down votes
Active

Goal 2: Reduce Human Disease

Prevent cytopenia in septic patients

Sepsis is the leading cause of death in critically ill patients in the USA, affecting particularly young children and the elderly. A hallmark of septic shock patients upon diagnosis is peripheral blood cytopenia. This persistent cytopenia commonly affects myeloid, lymphoid and erythroid lineages resulting in immunosuppression and is a well-established predictor of fatal outcome. Clinical trials targeting the production ...more »

Submitted by (@ben.croker)

Voting

0 net votes
11 up votes
11 down votes
Active

Goal 1: Promote Human Health

Study wellness instead of diseases by longitudinal follow-up of frequent and long term blood donors

Blood donors (especially young donors) in general represent healthy populations. Longitudinal follow-up of frequent and long term blood donors can be useful to establish data and sample sources for the study of wellness, instead of disease (especially for blood diseases). Not only it can be used as healthy controls, it can also be used to predict the wellness factors such as genetic variation, life style, exercise patterns, ...more »

Submitted by (@yanyunw)

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Lipid and lipoprotein metabolism in the CNS

The analysis of lipoprotein metabolism has traditionally been restricted to the easily accessible circulation and peripheral tissues. Very little work has been done behind the blood brain barrier, where many of the lipid carrying or metabolizing genes are also expressed. Yet we know very little about their functions there, although for instance ApoE4 is THE primary risk factor for late-onset Alzheimer's disease. Conventional ...more »

Submitted by (@joachim.herz)

Voting

-4 net votes
7 up votes
11 down votes
Active

Goal 2: Reduce Human Disease

What new methods of platelet preparation, processing, and storage are needed for hemostasis in various clinical conditions?

The limitations of 5-day 22˚ C storage significantly impacts platelet availability. It is critical that we develop new methods of collection, processing, storage to extend the storage time of platelets, and evaluate the use of whole blood. The attributes of these products must be understood to optimally alignment product attributes, clinical efficacy and safety with hemostatic needs in a variety of clinical states. Specifically, ...more »

Submitted by (@bldbuddy)

Voting

14 net votes
34 up votes
20 down votes
Active

Goal 2: Reduce Human Disease

Transplantation across HLA barriers in aplastic anemia

Allogeneic stem cell transplantation is curative in aplastic anemia with much less intrinsic toxicity than transplantation in hematologic malignancies. The recent BMT-CTN trial demonstrated 97% survival at one year with little subsequent decline. However patients without matched related or unrelated donors have graft-rejection rates of up to 50%. Preliminary data from the Netherlands suggests that anti-thymocyte globulin ...more »

Submitted by (@jantin)

Voting

110 net votes
137 up votes
27 down votes
Active

Goal 3: Advance Translational Research

Tools to facilitate availability and safe use of innovative blood products and their analogs

Novel blood products are being developed based on innovative science (e.g., ex vivo manufactured RBC and platelets, and platelet and plasma derived hemostatic products). However, there is a significant lag in the development of appropriate tools and model systems, which poses a challenge when evaluating such products for regulatory approval.

Submitted by (@chintamani.atreya)

Voting

12 net votes
17 up votes
5 down votes
Active

Goal 2: Reduce Human Disease

Biology of Red Blood Cell Alloimmunization

What determines which individuals will develop RBC alloimmune responses resulting in clinically meaningful sequelae? This question encompasses: 1) the generation of alloantibodies that limit the availability of compatible blood or cause hemolytic disease of the fetus or newborn (HDFN); 2) the distinction between clinically significant and insignificant alloantibody responses, especially within alloantibody specificities ...more »

Submitted by (@nareg.roubinian)

Voting

44 net votes
58 up votes
14 down votes
Active